A novel drug candidate for the treating schizophrenia.

Weight gain is certainly a common and relevant metabolic side-effect of atypical antipsychotic medicines clinically, and olanzapine has among the highest incidences and most significant amounts of excess weight gain among the widely prescribed items in this class of drugs. Related StoriesResearchers examine neuroanatomical signature of schizophrenia in different ethnic groupsResearchers match certain schizophrenia symptoms to features of the brain's anatomyNew initiative aims to get samples from schizophrenia sufferers across the globe Based on the positive results of the phase 1 study, Alkermes plans to initiate a phase 2 dose-ranging study of ALKS 3831 in mid calendar 2013. This study will evaluate ALKS 3831's safety and effects on metabolic outcomes, including pounds gain, in individuals with schizophrenia.Given this guidance, our path to market is now clear. We think that ARX-01 can make a meaningful effect on affected individual lives by addressing the current shortcomings of IV PCA by reducing invasiveness, reducing unintended dosing mistakes, increasing patient mobility and simplifying the needs on healthcare providers. .. Aeterna Zentaris selects optimized Erk inhibitor molecule for further development Aeterna Zentaris Inc. today announced it offers chosen an optimized Erk inhibitor molecule for development, thus achieving another essential milestone in the advancement of a new class of potential cancer treatments.